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ABSTRACT 
MicroRNAs (miRs) have emerged as useful biomarkers for different disease states, including allergic inflammatory 
diseases such as asthma and eosinophilic esophagitis (EoE). Serum miRs are a possible non-invasive method for 
diagnosis of such diseases. We focused on microRNA-21 (miR-21) levels in serum, in order to assess the feasibility 
of using this gene as a non-invasive biomarker for these diseases in the clinic, as well as to better understand the 
expression pattern of miR-21 in allergic inflammation. We used quantitative PCR (QPCR) to assay miR-21 and 
other control miRs in esophageal biopsies from EoE patients and serum samples from EoE and asthma patients. 
Serum levels of miR-21 were significantly elevated in patients with asthma, whereas serum miR-21 levels were not 
associated with the presence of allergen-specific IgE (i.e. atopy). Esophageal biopsies showed a large elevation of 
miR-21 in EoE and an increase in miR-21 in EoE serum. Control U6 miR did not vary between asthma and control 
patients, however EoE serum had significantly decreased U6 microRNA compared to controls. The decreased U6 in 
EoE sera did not completely account for the relative increase in miR-21 in the sera of EoE patients. We report for 
the first time that miR-21 is elevated in the sera of both asthma and EoE patients.  We find no relation between 
serum miR-21 levels and atopy. Our results thus suggest miR-21 is a novel biomarker for human allergic 
inflammatory diseases. 
 
 
 
 
 
 
 
 
Introduction: 
 
Micro-RNAs (miRs) are short 19-25 nucleotide long transcripts that are important repressors of gene 
expression at the post-transcriptional level (1).  MiRs are commonly elevated in cancer, autoimmunity and 
inflammation (2, 3), and thus miRs have been extensively examined as sensitive biomarkers for disease.  Due to the 
increased prevalence of allergic disease in recent decades (4), there is great interest in developing new approaches 
for analyzing and treating allergic diseases such as asthma. MicroRNA-21 (miR-21) expression is increased in 
allergic airway inflammation in mice, an asthma-like disease (5-7). Mir-21 expression is also increased in the 
allergic disease eosinophilic esophagitis (EoE) (8). Therefore, miR-21 appears to be a biomarker for Th2-type 
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allergic disease. Functionally, miR-21 can promotes Th2 responses by two different pathways. First, miR-21 can 
repress IL-12 gene expression, thus inhibiting Th1 responses and favoring Th2 responses (5, 6). Second, miR-21 can 
directly promote Th2 differentiation in a T cell intrinsic manner, by increasing Gata3 and IL-4 expression at early 
points after T cell activation (9).  
Since miRs are useful biomarkers for disease, miRs found in serum or “circulating miRs” represent a 
powerful method to assess disease in readily accessible clinical samples (10).  In a mouse model of asthma, we were 
able to detect elevated miR-21 in the serum of mice with severe airway inflammation (7). In this study, we set out to 
determine if we could detect increased miR-21 in the serum of human asthma patients.  We also sought to better 
understand the relationship between miR-21 and human allergic disease by analyzing miR-21 levels in serum from 
pediatric EoE patients.  We further tested whether miR-21 was generally associated with atopy, as defined by serum 
IgE levels. We have found that serum miR-21 is significantly elevated in both asthma and EoE patients. 
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Materials and Methods 
Patient Groups and Clinical samples: The collection and analysis of control, EoE patient and asthma 
patient samples were approved by the Institutional Review Board of Indiana University and required parental 
consent for samples from infants and children, following Declaration of Helsinki principles. Clinical samples were 
taken from two sets of patient cohorts described previously for asthma (11) and for EoE (12). Asthma samples and 
EoE samples each had separate study-specific controls. Asthma and control patients were enrolled into the study as 
infants for eczema presentation, and then were followed longitudinally for development of allergic disease. EoE and 
control patients were enrolled into the study at various ages, after referral to the gastroenterology clinic and 
subsequent esophagogastroduodenoscopy (EGD). Patient information for the two sets of patient samples is 
described in Table 1 for asthma and Table 2 for EoE. 
MicroRNA analysis: MicroRNAs from esophageal biopsies and human serum were isolated using the 
miRNeasy isolation kit (Qiagen). Esophageal biopsy and serum samples were obtained as frozen specimens.  Biopsy 
samples were immediately lysed while frozen, whereas serum was thawed prior to miR isolation. Generally, 
microRNA was isolated from 0.5 ml of serum. QPCR was performed using TaqMan microRNA assays (Applied 
Biosystems), according to the manufacturer’s protocol, and roughly 20% of the sample was used for the preparation 
of each specific miR cDNA. Normalization of miR-21 and miR-22 was performed using U6 RNA as control. 
Quantitative real-time PCR was performed by assaying each sample in triplicates, including no-template controls, on 
a Stratagene Mx3000P real-time PCR system. Relative expression was calculated using the delta-delta CT (ddCT) 
method. 
IgE quantitation: Serum IgE values were taken from a previous study (11). 
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Results 
Increased miR-21 was previously observed in the serum of mice with severe airway inflammation (7), thus 
we set out to test if circulating miR-21 was elevated in human asthma. We analyzed serum miR-21 levels in 
pediatric patients recruited into a study on the development of asthma.  The patients were recruited as infants, based 
on a diagnosis of eczema, and subsequently characterized for atopic status and the development of asthma (11).  We 
assessed serum levels of miR-21 in a set of patients that had been analyzed at age 5 for asthma status. We thus tested 
samples from 8 control patients without asthma and 8 patients with asthma. As shown in Figure 1, we found that 
serum miR-21 increased in the asthma patients by 2.7-fold, with a p value of 0.018. We also analyzed the expression 
of miR-22, which we found previously to be increased in the lungs of mice with severe airway inflammation 
(unpublished data). In contrast to miR-21, miR-22 was not increased in the serum of patients with asthma (Figure 1). 
In our selected patients, 8 out of 16 patients were atopic, as defined by the presence of IgE for specific antigen (11). 
However, the rate of atopy was similar between asthmatic and non-asthmatic patients (Table 1). Asthmatic patients 
had on average a two-fold increase in serum IgE over non-asthmatic patients (130 ± 26 IU/ml versus 61 ± 25 IU/ml, 
Table 1), however, the difference in IgE level was not significant (p = 0.24), due to the degree of variation. To 
further determine whether serum miR-21 levels associated with serum IgE levels, we directly compared these two 
parameters in a curve-fit linear regression analysis. As shown in Figure 2, serum miR-21 levels correlate very poorly 
with serum IgE levels, and thus miR-21 levels did not associate positively or negatively with atopy. We conclude 
that miR-21 levels are a novel serum biomarker for asthma, independent of atopic status.  
We next wondered if elevated miR-21 was a general marker for allergic inflammatory disease in humans, 
and obtained samples from EoE and control patients. We initially tested esophageal biopsies from EoE and control 
patients for miR-21 expression, and found that, similar to previous reports (8, 13) miR-21 expression is very 
significantly increased in EoE biopsies compared to control biopsies (Figure 3).  However, we observed a greater 
fold elevation in miR-21 in EoE, almost 50-fold on average, than in the two other studies (8, 13), who observed a 
roughly 4-fold increase in miR-21 in EoE compared to non-EoE. The expression of miR-22 increased roughly two-
fold in EoE biopsies (Figure 3), but the difference was not significant.  Next, we assessed miR-21 in serum from 
EoE patients (Figure 4).  Compared to controls, we observed an average of 30-fold increase in serum miR-21 levels 
in EoE patients, with a high degree of statistical significance. MiR-22 was not detected in the serum of EoE or 
control patients (data not shown).  
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 Our results contrasted with that of Lu et al who detected less increase in miR-21 in esophagus in EoE, and 
little to no levels of circulating miR-21 in EoE (8). One key factor in miR analysis is the control miR used for 
normalization (8). We therefore analyzed the specific expression of U6 miR that we used for normalization, in our 
different samples (Figure 5). U6 levels were essentially constant between control and asthma sera, and between 
control and EoE biopsy. However, we found that U6 levels were significantly lower in EoE sera compared to control 
sera (represented as higher Ct value by a factor of 3.3). This average decrease in U6 by about 10-fold in EoE sera 
can account for the relative increase in miR-21 we observe in some EoE sera, but sera from 11/18 EoE patients have 
increases in miR-21 that cannot be accounted for the decreased U6 (data not shown). Further, the U6 values in 
control and EoE sera were remarkably consistent, with a low standard deviation. The miR-21 values however, were 
much more variable and may reflect active more active inflammation in EoE patients than in other patients.  
However, there was no association between eosinophil counts in esophageal biopsies from EoE patients and miR-21 
levels (data not shown).  Serum levels of miR-21 may therefore reflect other aspects of the inflammatory disease 
than just the degree of eosinophil infiltration into the esophagus in EoE. 
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Discussion 
Overall, our results indicate that elevated circulating miR-21 can potentially serve as a biomarker for 
allergic inflammatory diseases such as asthma and EoE. Overall, we find that EoE patients have a much greater 
increase in serum miR-21 than asthmatic patients, however this difference may relate to the severity of disease at the 
time of sample collection, rather than a difference in disease type.  Further research will be required to determine if 
serum miR-21 levels are a useful predictor of the development of asthma, EoE or other allergic inflammatory 
diseases.  
Our miR-21 results contrast with that of Lu et al (8) who detected little to no levels of circulating miR-21 
in EoE, as well as a lower level of miR-21 in esophageal biopsy samples. Some of the possible explanations for our 
ability to detect elevated miR-21 in EoE sera and greater increases of miR-21 in biopsies compared to Lu et al are 
differences in 1) disease severity between patients in the two studies, 2) control patients between the two studies and 
3) miR-21 assay sensitivity. As judged by eosinophil infiltration into the esophagus, the level of disease in our EoE 
population is not more severe than in the Lu et al study; in fact, our study used a slightly lower cut-off for eosinophil 
infiltration than Lu et al (15 per high powered field versus 24 per high powered field). In terms of control groups, 
for the serum analysis, Lu et al specifically compared circulating miR-21 in EoE patients to healthy atopic patients. 
Our controls in the EoE study were patients who had undergone esophagogastroduodenoscopy (EGD) for a variety 
of non-specific reasons but had normal histology on biopsies of the upper gastro-intestinal tract. However, patient 
history (Table 2) indicates that our control patients had similar levels of allergy and asthma as the EoE patients.  
Furthermore, we did not observe an association between the level of miR-21 expression and allergy or atopy, either 
in the asthma group or the EoE group. Thus, we conclude that the best explanation for our results is that our miR-21 
assay was more sensitive, even though the reagents we used were very similar to the reagents used by Lu et al.  One 
major difference with our results on serum miR-21 in EoE is the control miR used to normalize miR-21 levels. Lu et 
al used miR-16 as a control for the circulating miRs in EoE, whereas we used U6.  We tested miR-16 in our EoE 
sera but found that it gave much lower signal than the U6 (data not shown). We therefore decided that U6 was a 
more robust control for the EoE sera. Although still easily detectable in our assay, we did note that U6 levels were 
consistently decreased in EoE sera (Figure 5). Altered U6 expression in serum has been previously shown in breast 
cancer (14), and altered serum levels of U6 miR may be a biomarker for chronic disease.  Interestingly, in breast 
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cancer, serum U6 levels were elevated (14), whereas we find in EoE that serum U6 levels were decreased. This 
suggests there may be disease-specific regulation of U6 miR levels in the serum.  
Possibly the most important different between the Lu et al study and ours, is that they used “plasma”, 
whereas we used serum.  The major difference between plasma and serum is the presence of clotting factors, and 
conceivably clotting factors could impact miR stability or isolation. Another possibility that is difficult to rule out is 
cellular contamination of plasma and serum with small numbers of cells or lysed blood cells (15), and possibly our 
EoE results may be explained by contamination of the sera with cellular debris.  However, the key point is that we 
observe highly significant differences between control and EoE and between control and asthma samples.  This may 
indicate that blood cells from patients with allergic inflammatory disease have a greater propensity to undergo lysis 
during sample collection.  Patients with the most severe ongoing inflammation may be especially prone to this 
phenomenon. This does not mitigate the possibility of using a miR-21-based assay to diagnose allergic inflammatory 
disease in human patients.   
One likely source of the elevated serum miR-21 we observe in EoE and asthma is eosinophils, since 
eosinophils are strongly increased in both diseases and they express high levels of miR-21 (16). The eosinophils in 
EoE and asthma may secrete miR-21 via exosomes, or miR-21 is released from eosinophils when they die in the 
course of the disease. A possible source of serum miR-21 in specifically EoE is release from inflamed esophagus 
epithelium, since normal esophagus can expresses miR-21 (17). MiR-21 is increased during Th2 inflammation in 
EoE and in airway inflammation (5, 18), and we observed striking levels of miR-21 expression in lung epithelium in 
Th2-type airway inflammatory disease (7). MiR-21 is also up-regulated in Th2 cells (9), and could be released from 
these cells also by exosomes or after their death. 
MiR-21 is most well-known for being an “oncomiR” favorable to cancer cell growth, and as one of the 
most commonly up-regulated microRNAs in cancer (2, 19, 20). The cytokine-activated transcription factor Stat3 is 
positive regulator of miR-21 transcription, and may be a common pathway for increased miR-21 expression both in 
cancer and in inflammation (21). We have shown that miR-21 is activated in Th2 cells by Stat3 (9), and therefore 
Stat3 activity appears to link much of the aberrant miR-21 expression associated with disease. 
 
Conclusion 
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We have shown here, for the first time that miR-21 is elevated in the sera of both asthma and EoE patients, 
whereas we find no relation between serum miR-21 levels and atopy. Our results thus suggest miR-21 can be used a 
novel and sensitive biomarker for severe allergic inflammatory diseases in patients. Our results warrant a further 
study into miR-21-based assays for testing different allergic diseases, using a variety of conditions. 
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Figure Legends 
 
Figure 1. Serum miR-21 is increased in asthma. Quantitative PCR (QPCR) analysis of miR-21 (A) and miR-22 
(B) expression in serum samples prepared from 5 year old patients presenting at 1 year of age with 
dermatitis and then monitored for allergy symptoms and the development of asthma. Relative miR 
expression is shown, with average dCT values from control patient samples set as 1, and fold-change 
calculated by the ddCT method.  
 
Figure 2. Serum miR-21 does not correlate with serum IgE levels. Pearson correlation analysis between IgE 
levels (in IU) and miR21 levels (fold-change from average non-asthmatic control). N = 16 total patients, 8 
with asthma and 8 without asthma. *p<0.05 (two-tailed Student’s t-test) (error bars, s.e.m.) 
 
Figure 3. MicroRNA-21 is greatly elevated in the esophagus of patients with eosinophilic esophagitis. 
Quantitative PCR (QPCR) analysis of miR-21 (A) and miR-22 (B) expression in esophageal biopsy RNA. 
Relative miR expression was calculated as described in Figure 1. 
 
Figure 4. MicroRNA-21 is significantly elevated in the serum of patients with eosinophilic esophagitis. 
Quantitative PCR (QPCR) analysis of miR-21 in serum from non-EoE controls and eosinophilic 
esophagitis (EoE) patients, normalized using U6 as control. Relative miR expression was calculated as 
described in Figure 1. MiR-22 was not detected at significant levels in serum from either EoE or non-EoE 
patients.  N = 18subjects per group. ***p<0.001 (two-tailed Student’s t-test) (error bars, s.e.m.)  
 
Figure 5. U6 microRNA expression is significantly decreased in the serum of patients with eosinophilic 
esophagitis. Quantitative PCR (QPCR) analysis of U6 microRNA in serum from all samples tested in this 
study. Data shown is raw QPCR Ct values, which correspond to the amplification cycle where the target is 
first detected. Higher Ct values mean less RNA target in the sample.  EoE sera have on average a Ct value 
of 35.5 compared to a 32.2 Ct value for controls. 
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Table 1. Asthma study patient information 
Non-asthma (n = 8) Asthma (n = 8) 
Age (years) 5 ± 0.2 5 ± 0.2 
SCORAD index 3 ± 1.7 6 ± 1.7 
IgE specific for egg 
or milk 
0% 25% 
IgE specific for any 
known antigen 
50% 63% 
IgE (IU/ml) 61 ± 25 130 ± 26 
Values are average ± SEM. None of the parameters were significantly different between the patient 
groups.  
Table 2. EoE study patient information 
Non-EoE (n = 8) EoE (n = 7) 
Age (years) 7 ± 2 7 ± 1 
Asthma diagnosis 25% 17% 
Known allergy 63% 83% 
Eosinophil count in 
esophageal biopsy (#/hpf) 
<15 49 ± 12 
Values are average ± SEM. The only significant difference between the patient groups was eosinophil count (p < 0.01).  
